Omidenepag isopropyl is a novel, selective, non-prostanoid EP2 receptor agonist. It can be used for treatment of open-angle glaucoma and ocular hypertension. Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag.[5] Omidenepag is a selective prostaglandin E2 receptor agonist. It was approved for medical use in Japan in 2018, and in the United States in September 2022.
Preparation of pyridylaminoacetic acids for treatment of respiratory diseases
By: Iwamura, Ryo; et al
World Intellectual Property Organization, WO2009113600 A1 2009-09-17
